Results of 2022 Annual General Meeting

RNS Number : 3365I

Aptamer Group PLC

01 December 2022

 

01 December 2022

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Results of 2022 Annual General Meeting

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, today announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today at 13:30 GMT at the offices of Liberum, Level 12 Ropemaker Place, 25 Ropemaker Street, London, EC2Y 9LY, all Resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 01 November and the full poll results will be made available on the Aptamer website later today.

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley    [phone]

SPARK Advisory Partners Limited - Nominated Adviser  

Andrew Emmott / Adam Dawes  [phone]

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Will Hall / Cara Murphy   [phone]

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone       [phone]

[e-mail]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

 

END

 

 

RAGBRBDDBGGDGDB